Bebb, GwynKopciuk, KarenTudor, Roxana2016-10-042016-10-0420162016Tudor, R. (2016). Treatment at Disease-progression in EGFR-mutated NSCLC Patients: Results from a single Canadian Institution (Master's thesis, University of Calgary, Calgary, Canada). Retrieved from https://prism.ucalgary.ca. doi:10.11575/PRISM/28522http://hdl.handle.net/11023/3403Optimal treatment beyond disease-progression (PD) in non-small cell lung cancer (NSCLC) patients harboring activating epidermal growth factor receptor (EGFR) mutations, treated with tyrosine kinase inhibitors (TKIs), is not well-defined. In this retrospective study, the following aims were set out: 1) compare outcomes and profile of EGFRmut+ NSCLC patients to large cohorts of lung-cancer patients from the Glans-Look lung cancer database -GLD; 2) examine the frequency of continuing TKI treatment beyond PD in EGFRmut+ patients; 3) examine overall survival (OS) and post-progression survival (PPS) according to clinicopathological characteristics and; 4) propose a new PD-scoring model to help guide subsequent treatment formulation. Compared to the GLD-NSCLC cohort without systemic chemotherapy, EGFRmut+ patients were more likely to be younger, female and Asian. Further, continuing TKI treatment beyond PD was associated with improved OS and PPS vs. discontinuation of TKI. A non-independent relationship between EGFRmutation type and smoking history was identified.engUniversity of Calgary graduate students retain copyright ownership and moral rights for their thesis. You may use this material in any way that is permitted by the Copyright Act or through licensing that has been assigned to the document. For uses that are not allowable under copyright legislation or licensing, you are required to seek permission.OncologyEGFRmut+PDTKImaster thesis10.11575/PRISM/28522